Comparison of ELISA with automated ECLIA for IL-6 determination in COVID-19 patients: An Italian real-life experience.
| Autor: | Romano F; General Laboratory, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy., Lanzilao L; General Laboratory, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy., Russo E; Department of Experimental and Clinical Medicine, University of Florence, 50121, Florence, Italy., Infantino M; Immunology and Allergology Laboratory Unit, S. Giovanni di Dio Hospital, 50143, Florence, Italy., Nencini F; General Laboratory, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy., Cappelli G; Department of Experimental and Clinical Medicine, University of Florence, 50121, Florence, Italy., Dugheri S; Department of Experimental and Clinical Medicine, University of Florence, 50121, Florence, Italy., Manfredi M; Immunology and Allergology Laboratory Unit, S. Giovanni di Dio Hospital, 50143, Florence, Italy., Fanelli A; General Laboratory, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy., Amedei A; Department of Experimental and Clinical Medicine, University of Florence, 50121, Florence, Italy., Mucci N; Department of Experimental and Clinical Medicine, University of Florence, 50121, Florence, Italy. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Practical laboratory medicine [Pract Lab Med] 2024 Apr 01; Vol. 39, pp. e00392. Date of Electronic Publication: 2024 Apr 01 (Print Publication: 2024). |
| DOI: | 10.1016/j.plabm.2024.e00392 |
| Abstrakt: | Objectives: Coronavirus disease 2019 (COVID-19) has a wide spectrum of clinical severity. A cytokine storm is associated with COVID-19 severity. Of these, IL-6 is significantly associated with higher mortality and is also a marker for predicting disease prognosis. IL-6 may act as a target for therapeutics and, a blockade of IL-6 function by Tocilizumab has been described as a treatment of the inflammatory process COVID-19-related. This study aims to describe our experience comparing two different methods, in detail Human IL-6 Instant ELISA and the Elecsys IL-6 based on ECLIA, for the IL-6 assessment. Design and Methods: IL-6 levels from serum samples of 104 COVID-19 patients, admitted to the AOU Careggi (Hospital in Florence -Italy), were assessed by using the two above-mentioned methods, and the results were analysed through Passing-Bablok regression fit and Bland-Altman plot. Results: The regression exhibited a linear relation between the methods with a regression equation (y = - 0.13 + 0.63 x; 95 % C.I. intercept = - 0.13 to 4.55; 95 % C.I. slope = 1.03 to 1.26 with R 2 = 0.89, p > 0.05), showing a positive slope. The agreement of the two methods reported a bias of -25.0 pg/mL. Thus, the two methods correlate but do not agree in terms of numeric results. Conclusions: The two assays showed good comparability. However, because of the extremely wide linear range of the ECLIA, its throughput and its capacity for immune profiling, it represents an interesting emerging technology in the immunology field. Competing Interests: Francesca Romano: None. Luisa Lanzilao: None. Edda Russo: None. Maria Infantino: None. Francesca Nencini: None. Giovanni Cappelli: None. Stefano Dugheri: None. Mariangela Manfredi: None. Alessandra Fanelli: None. Amedeo Amedei: None. Nicola Mucci: None. (© 2024 The Authors.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|